Abstract:132 Background: The standard treatment for unresectable recurrent rectal cancer (URRC) is chemotherapy (CTx) regardless of local recurrence (LR). Approximately 80% of patients with LR experience LR-related pain, making these patients difficult to treat, especially the timing of radiotherapy (RT). However, the impact of LR and the appropriate timing of palliative RT on prognosis in patients with URRC remains unclear. Methods: This retrospective study included patients with URRC who had an ECOG Performance Status (PS) of 0–2 and received fluoropyrimidines plus oxaliplatin and/or irinotecan as first-line CTx between September 2006 and December 2020 at a single institution. Patients were divided into two groups: patients with LR (LR+) and patients without LR (LR−). Progression-free survival (PFS), overall survival (OS), and post-progression survival (PPS) after first-line CTx were compared between the two groups. The association between receiving palliative RT for LR-related symptoms until disease progression after first-line CTx and the proportion of patients receiving subsequent second-line CTx was also evaluated in the LR+ group. Multivariate Cox analysis, including variables with p < 0.10 in univariate analyses, was performed for PPS. Results: The LR+ and LR− groups included 49 and 99 patients, respectively. No significant differences in the baseline characteristics were detected between the two groups, except liver metastasis, which occurred less frequently in the LR+ group. OS and PPS were shorter in the LR+ group compared with the LR- group (median OS, 33.4 vs. 48.2 months; hazard ratio [HR], 1.52; p = 0.05; median PPS, 17.2 vs. 23.5 months; HR, 1.77; p = 0.01). PFS was similar between the two groups (median PFS, 13.0 vs. 15.8 months; HR, 1.18; p = 0.39). Fewer patients in the LR+ group received second-line CTx compared with the LR- group (68 vs. 83%, p = 0.06). The proportions of patients with PS ≥ 1 (78 vs. 52%, p = 0.007) and PS deterioration at progression after first-line CTx (59 vs. 27 %, p = 0.002) were higher in the LR+ group compared with the LR group-. The most common cause of PS deterioration in the LR+ group was LR-related pain (77%). Among patients with LR-related pain, the proportion of patients receiving subsequent second-line CTx was numerically lower in patients who did not receive palliative RT than in patients who did receive palliative RT until disease progression after first-line CTx (75 vs. 54%, p = 0.23). Multivariate analysis revealed that receiving subsequent second-line CTx was an independent prognostic factor for PPS in LR+ patients (adjusted HR, 4.77; p = 0.006). Conclusions: The presence of LR is associated with poor prognosis in URRC, which may be due to worsening PS caused by LR-related symptoms and the lower proportion of subsequent CTx. Thus, palliative RT should be recommended more actively when LR becomes symptomatic.

Incorporation of Radiotherapy in the Multidisciplinary Treatment of Isolated Retroperitoneal Lymph Node Recurrence from Colorectal Cancer

Palliative beam radiotherapy offered real-world survival benefit to metastatic rectal cancer: A large US population-based and propensity score-matched study.

Dosimetry, Efficacy, and Safety of Three-Dimensional Printing Noncoplanar Template-Assisted and CT-guided 125I Seed Implantation for Recurrent Retroperitoneal Lymphatic Metastasis after External Beam Radiotherapy

Salvage Radiotherapy Strategy and Its Prognostic Significance for Patients With Locally Recurrent Cervical Cancer After Radical Resection: a Retrospective 10-year Analysis

Impact of Clinical-pathological Factors on Locoregional Recurrence in Mastectomy Patients with T1-2N1 Breast Cancer: Can We Omit Adjuvant Radiotherapy?

The Use of Re-irradiation in Locally Recurrent, Non-metastatic Rectal Cancer

Long-Term Outcomes and Prognostic Analysis of Computed Tomography-Guided Radioactive 125I Seed Implantation for Locally Recurrent Rectal Cancer After External Beam Radiotherapy or Surgery

Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?

Efficacy and Safety of Radiotherapy Combined with Raltitrexed and Irinotecan for Treating Unresectable Recurrent Colorectal Cancer: a Single-Arm Phase II Trial

Prognostic impact of local recurrence and timing of palliative radiotherapy in patients with unresectable recurrent rectal cancer.

The Role of Simultaneous Integrated Boost in Locally Advanced Rectal Cancer Patients with Positive Lateral Pelvic Lymph Nodes

Salvage Reirradiation with Proton Beam Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer

Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery

A Real-World, Population-Based Retrospective Analysis of Therapeutic Survival for Recurrent Localized Renal Cell Carcinoma After Nephrectomy

Radiotherapy Can Improve The Disease-Free Survival Rate In Triple-Negative Breast Cancer Patients With T1-T2 Disease And One To Three Positive Lymph Nodes After Mastectomy

A Study of Postoperative Radiotherapy in Patients with Non–small-Cell Lung Cancer: a Randomized Trial

Radiotherapy following modified radical mastectomy significantly improves locoregional control in patients with Rec-/HER-2+ locally advanced breast cancer

Patterns of Failure and Implications for Clinical Target Volume Definition of Locally Advanced T4b Rectal Cancer Identified with Magnetic Resonance Imaging and Treated Using Neoadjuvant Chemoradiotherapy and Surgery.

Special Issue “the Advance of Solid Tumor Research in China”: Presurgical Therapy in the Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy

Management of Clinically Involved Lateral Lymph Node Metastasis in Locally Advanced Rectal Cancer: A Radiation Dose Escalation Study

Retroperitoneal nodal metastases from colorectal cancer: Curable metastases with radical retroperitoneal lymphadenectomy in selected patients